Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

1. Metastatic gastric cancer patients who failed standard treatment will be enrolled in this study.
2. After consent form, patient-derived cancer cell will be collected and tested with 3 kinds of drugs (sunitinib, gefitinib, imatinib).
3. Drug sensitivity prediction software (IRCR-DReSS) will present level of sensitivity and patients will be treated with sensitive drugs.
4. Patients will be evaluated every 6 weeks.

Inclusion Criteria:

• age>-20
• metastatic gastric cancer
• life expectancy >-3 months
• ascites and pleural effusion that can be drained
• ECOG 0-2
• Proper organ function
• Patients who will be enrolled in sunitinib, gefitinib, imatinib clinical trial

Exclusion Criteria:

• HBeAg, HCV, HIV (+)
• Active infection
• Uncontrolled systemic disease